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Abstract

Objective
To evaluate whether nephrotoxicity differs between nafcillin and piperacillin-tazobactam in adult
hospitalized patients.

Introduction
Acute kidney injury (AKI) is a significant cause of morbidity and mortality in the inpatient
setting, with antibiotics being a significant contributor. There is evidence of an increased risk of
nephrotoxicity with the combination of vancomycin and piperacillin-tazobactam compared to
vancomycin and cefepime or vancomycin alone. It is unknown whether this effect is exclusive
for piperacillin-tazobactam. Therefore, in order to promote optimal medication therapy for
inpatient bacterial infections, there is a need to assess the persistence of this difference in other
beta-lactam antibiotics.

Methods
A single-center, retrospective cohort study was performed utilizing electronic health records at
University of Kentucky Healthcare. Adult hospitalized patients being treated with nafcillin or
piperacillin-tazobactam from September 1, 2010 to September 1, 2014 were included in the
study. Age, sex, Charlson Comorbidity Index, baseline creatinine clearance, dehydration,
hypotension, exposure to concomitant nephrotoxins, and duration of therapy were evaluated. The
primary outcome was AKI as defined by the RIFLE criteria (risk, injury, failure, loss of kidney
function, and end-stage kidney disease), where risk, injury, and failure were defined as a 25%,

4
50%, and 75% decrease in glomerular filtration rate from baseline, respectively. Secondary
outcomes included time to AKI from initiation of antibiotics, hospital length of stay, and
mortality.

Results
Of the 3,393 patients included in this study, 272 were treated with nafcillin and 3,121 were
treated with piperacillin-tazobactam. Overall incidence of AKI was 19.49% in the nafcillin group
and 7.72% in the piperacillin-tazobactam group (p<0.0001). After adjusting for age, sex,
Charlson Comorbidity Index, baseline creatinine clearance, hypotension, number of concomitant
nephrotoxins, and duration of therapy, those in the nafcillin group had 2.002 (95% CI 1.3572.953) times the odds of AKI compared to those in the piperacillin-tazobactam group. Time to
AKI, hospital length of stay, and inpatient mortality were also significantly higher in the nafcillin
group.

Conclusions
The results from this study suggest that nafcillin has a significantly greater potential for
nephrotoxicity compared to piperacillin-tazobactam. Future research may involve further
evaluating the risk factors of AKI, indication, and dosing schedule of these or other antibiotics in
a larger population.
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Introduction

The incidence of acute kidney injury (AKI) is estimated to be between 5.7% and 18.0%.
Development of AKI can lead to significant increases in length of stay, healthcare costs, and
mortality, with in-hospital mortality ranging from 50.5% to 76.8%.1-3 AKI can occur as a result
of a number of factors including cardiac insufficiency, sepsis, malignancy, liver insufficiency,
and autoimmune diseases.3 Drug-induced nephrotoxicity is also a significant cause of AKI and
has been shown to be associated with angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin receptor blockers (ARBs), acyclovir, aminoglycosides, amphotericin B, beta-lactam
antibiotics, IV contrast, and non-steroidal anti-inflammatory drugs (NSAIDs), among others.4,5

Piperacillin-tazobactam is a beta-lactam/beta-lactamase inhibitor combination broad-spectrum
antibiotic commonly used to empirically treat for many gram-positive and gram-negative
infections. Incidence of nephrotoxicity in piperacillin-tazobactam has been reported to be 9.0%
to 18.2%.6-8 There is little data demonstrating the mechanism of nephrotoxicity of piperacillintazobactam, although in few studies indicate acute interstitial nephritis (AIN) is the most likely
cause.9-12,37 Piperacillin-tazobactam has also been shown to cause a lower rate of renal recovery
compared to other antibiotics.13

The combination of vancomycin, a glycopeptide antibiotic used to treat gram-positive infections,
with piperacillin-tazobactam has a higher incidence of nephrotoxicity than vancomycin alone.14,15
In yet to be published data from a study conducted at the University of Kentucky, the
combination of vancomycin and piperacillin-tazobactam also had a higher incidence of
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nephrotoxicity than combination of vancomycin and cefepime, another broad-spectrum betalactam antibiotic. It is unknown whether this effect is exclusive for piperacillin-tazobactam or if
it also exists in other beta-lactam antibiotics.

Nafcillin is a narrow-spectrum beta-lactam antibiotic used most commonly as one of the first line
treatments for methicillin-sensitive Staphylococcus aureus (MSSA) infections. Incidence of
nephrotoxicity of nafcillin has been shown to be 11.4%.16 Nafcillin has been reported as the most
probable cause of acute interstitial nephritis (AIN) in a number of cases.17-19

The purpose of this study is to investigate the difference in nephrotoxicity between nafcillin and
piperacillin-tazobactam in adult hospitalized patients. The results of this study may aid in the
selection of medication therapy for inpatient bacterial infections.
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Methods

Study sample

A single-center, retrospective cohort study was conducted at University of Kentucky Healthcare,
a tertiary care academic medical center. All patients admitted between September 1, 2010 and
September 1, 2014 without renal dysfunction at initiation, chronic kidney disease, structural
kidney disease, or pre-existing dialysis were eligible for the study. Patients with kidney disease
at baseline were excluded to allow for assessment of the effects of the study antibiotics. Each
admission was treated as an independent event. Patients receiving either nafcillin or piperacillintazobactam were included. Patients were excluded from the piperacillin-tazobactam group if they
received therapy with vancomycin in order to isolate the effects of the study drug. Those in the
nafcillin group may have received up to 5 days of vancomycin or piperacillin-tazobactam to
remain in the study due to clinical use of nafcillin typically being after initial treatment with
more broad-spectrum empiric therapy. Other exclusion criteria include length of stay less than 2
days, age less than 18 years, baseline creatinine clearance greater than 4 times the standard
deviation of the mean or less than 30 mL/min, days of antibiotic therapy less than 2 days, and
AKI prior to treatment index, within 48 hours of treatment index, or greater than 7 days after
treatment was discontinued. Minimum limits were used for length of stay and duration of
antibiotic therapy to exclude AKI events due to previous exposures. These criteria were applied
for timeframe of AKI to limit events to those that occurred due to the study drugs. Patients who
did not have serum creatinine values were also excluded from analysis. This study was exempt
from IRB approval as only de-identified data were used.

8
Data collection and measures

Inpatient clinical data from September 1, 2010 to September 1, 2014 was gathered from the
University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust.
Information on age, sex, Charlson Comorbidity Index, baseline creatinine clearance,
dehydration, hypotension, receipt of concomitant nephrotoxins, and duration of antibiotic
therapy were collected. Many of these factors have the potential to increase risk of AKI.
Charlson Comorbidity Index is a measure of illness severity based on a patient’s medical history.
Baseline creatinine clearance was based on the first measured serum creatinine. Hypotension was
determined by the composite of hypotension diagnosis, mean arterial pressure less than 60
mmHg, and/or use of vasopressor or inotrope therapy. Concomitant nephrotoxins assessed
include acyclovir, aminoglycosides, amphotericin B, ACEIs, ARBs, colistin, cyclosporine,
foscarnet, IV contrast, loop diuretics, NSAIDS, sulfonamides, tacrolimus, and tenofovir. Patients
received one point for each of the nephrotoxins studied to give a total number of concomitant
nephrotoxins received. Duration of therapy was defined as the number of unique days patient
received at least one dose of study antibiotic.

Study outcomes

The primary outcome was the difference in AKI between nafcillin and piperacillin-tazobactam as
defined by the RIFLE criteria based on percent change from baseline creatinine clearance to
minimum creatinine clearance. This was evaluated both in patients being treated with nafcillin
with exposure to piperacillin-tazobactam and/or vancomycin for 5 days or less, as well as the
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nafcillin only group. The RIFLE criteria is the first consensus definition of AKI.20 Within the
RIFLE criteria there are 3 severity classes, risk, injury, and failure, which are a 25%, 50%, and
75% decrease in glomerular filtration rate (GFR) from baseline. GFR is a measure of kidney
function and is based on the adjusted Cockcroft-Gault equation. In addition, there are two
outcome classes, loss of kidney function and end-stage kidney disease. The current study did not
evaluate outcome classes because diagnosis based on duration of renal dysfunction is required, a
variable that was not collected. The RIFLE criteria has been largely validated to identify AKI,
classify severity, and correlate with patient outcome.21-24

Secondary outcomes include time to AKI from initiation of antibiotic therapy, hospital length of
stay, and mortality, where mortality is a composite of inpatient mortality and transfer to hospice
service.

Statistical analysis

Basic descriptive statistics were used to assess the characteristics of the study population.
Continuous variables were evaluated by Student’s T-test or, if data was not normally distributed,
Wilcoxon Rank Sum test. Data from continuous variables were reported as mean and standard
deviation as well as median with interquartile range. Categorical variables were analyzed using
Chi-Square test or, if there was a count of less than 5 in one of the cells of the contingency table
or if 25% or more cells had expected counts less than 5, results from Fisher's Exact test were
reported. Data from categorical variables were reported as number and percentage. All tests were
two-sided with significance defined as p < 0.05. Chi-Square test and Fisher’s Exact test were
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also used for the unadjusted analysis of the primary outcome of AKI overall and for risk, injury,
and failure classifications. Logistic regression was used for an adjusted analysis of the primary
outcome of AKI overall and for risk, injury, and failure classifications. Adjustment was made for
all variables that reached statistical significance in the bivariate analysis. Secondary outcomes
were analyzed using Student’s T-test or Wilcoxon Rank Sum test for continuous variables and
Chi-Square test for categorical variables. All statistical analysis was performed using SAS
Statistical software.
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Results

A total of 31,854 patients were screened for study participation (Figure 1). Based on antibiotic
exposure, length of stay less than 2 days, age less than 18 years, lack of serum creatinine values,
baseline creatinine clearance greater than 4 times the standard deviation of the mean (~406
mL/min) or less than 30 mL/min, days of therapy less than 2 days, and AKI prior to treatment
index, within 48 hours of treatment index, or greater than 7 days after treatment was
discontinued, 28,461 patients were excluded. The final sample consisted of 272 patients in the
nafcillin study group and 3,121 patients in the piperacillin-tazobactam study group.

Patient population

The mean age of patients in the nafcillin group was 47.49 ± 15.61 years and 53.28 ± 17.56 years
in the piperacillin-tazobactam group (p<0.0001) (Table 1). There were 64.34% males in the
nafcillin group and 49.15% in the piperacillin-tazobactam group (<0.0001). Charlson
Comorbidity Index was also statistically different between groups, with a mean score of 2.77 ±
3.19 in the nafcillin group and 3.47 ± 3.65 in the piperacillin-tazobactam group (p=0.0084).
Mean baseline creatinine clearance was 106.91 ± 42.73 mL/min in the nafcillin group and 100.38
± 42.87 in the piperacillin-tazobactam group (p=0.0161). Hypotension was observed in 51
(18.75%) of patients in the nafcillin group and 342 (10.96%) in the piperacillin-tazobactam
group (p=0.0001). Exposure to concomitant nephrotoxins was significantly different for ACEIs,
acyclovir, aminoglycosides, loop diuretics, NSAIDS, sulfonamides, tacrolimus, IV contrast, with
all but tacrolimus being higher in nafcillin. There was no colistin use in either group. The
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number of patients receiving 2, 3, and 4 or more concomitant nephrotoxins was also greater in
the nafcillin group (p<0.0001). Mean duration of therapy was longer in the nafcillin group, 8.46
± 9.96 days, compared to in the piperacillin-tazobactam group, 4.63 ± 2.67 days (p<0.0001). The
number of patients transferred to University of Kentucky Healthcare from an outside hospital
was 1,306 (38.49%), with a similar proportion in each group. There were no patients that
developed need for dialysis while inpatient.

Table 2 displays the antibiotic exposure for both study groups. In the nafcillin group, there were
two patients (0.74%) who received piperacillin-tazobactam, 90 (33.09%) who received
vancomycin, and 139 (51.10%) who received both piperacillin-tazobactam and vancomycin. 41
(15.07%) patients received nafcillin only.

Primary outcome

In the unadjusted analysis, AKI occurred in 53 (19.49%) nafcillin patients and 241 (7.72%)
piperacillin-tazobactam patients (p<0.0001). There were 38 (13.97%) patients classified as
having risk in the nafcillin group and 192 (6.15%) in the piperacillin-tazobactam group. Ten
(3.68%) of patients were classified as having injury in the nafcillin group and 37 (1.19%) in the
piperacillin-tazobactam group. Finally, 5 (1.84%) were classified as having failure in the
nafcillin group and 12 (0.38%) in the piperacillin-tazobactam group. All categories had higher
incidence of nephrotoxicity in the nafcillin group. In the nafcillin only group, AKI occurred in 9
patients (21.95%) compared to 241 (7.72%) in the piperacillin-tazobactam group (p<0.0001)
(Table 3).
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Adjustments were made for age, sex, Charlson Comorbidity Index, baseline creatinine clearance,
hypotension, number of concomitant nephrotoxins, and duration of therapy. In the adjusted
analysis, those in the nafcillin group had 2.002 (95% CI 1.357-2.953) times the odds of AKI
compared to those in the piperacillin-tazobactam group. Results were similar in the risk category
with the nafcillin group having 1.799 (95% CI 1.162-2.786) times the odds of risk compared to
those in the piperacillin-tazobactam group. The injury and failure categories were non-significant
with odds ratios of 2.246 (95% CI 0.958-5.264) and 2.357 (95% CI 0.685-8.113), respectively.
The odds of AKI in the nafcillin only group was 2.634 (95% CI 1.154-6.016) times that of the
piperacillin-tazobactam group (Table 4).

Secondary outcomes

The mean time to AKI was 6.00 ± 5.14 days in the nafcillin group and 4.69 ± 3.41 days in the
piperacillin-tazobactam group (p=0.0458). The mean hospital length of stay was 14.38 ± 12.69
days in the nafcillin group and 7.44 ± 7.55 days in the piperacillin-tazobactam group (p<0.0001).
Mortality occurred in 135 (3.98%) patients in the total study population, with 23 (8.46%) in the
nafcillin group and 112 (3.59%) in the piperacillin-tazobactam group (p<0.0001) (Table 5).
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Discussion

This study aimed to evaluate whether nephrotoxicity differs between nafcillin and piperacillintazobactam. The nafcillin group had 2.002 (95% CI 1.357-2.953) times the odds of AKI
compared to the piperacillin-tazobactam group after adjusting for age, sex, Charlson
Comorbidity Index, baseline creatinine clearance, hypotension, number of concomitant
nephrotoxins, and duration of therapy. This difference persisted in the risk category, however
was not statistically significant in the injury and failure categories. A similar result was seen
when limiting comparison to those who received nafcillin only. This study suggests that betalactam antibiotics overall may contribute to nephrotoxicity in adult hospitalized patients, with
nafcillin carrying a significantly larger burden of AKI than piperacillin-tazobactam.

Results from this study agree with current literature, although the incidence of AKI in nafcillin
was higher compared to previous studies. In a yet to be published study from the University of
Kentucky, vancomycin in combination with piperacillin-tazobactam had a significantly higher
incidence of nephrotoxicity than vancomycin in combination with cefepime, with rates of 30%
and 18%, respectively (p<0.0001).14 The incidence of AKI was also shown to be different
depending on the dosing scheme of piperacillin-tazobactam, with a higher rate in those who
received 4.5 grams every 6 hours compared to those who received 3.375 grams every 6 hours. In
a study evaluating a population of diabetic patients with osteomyelitis, acute renal failure was
seen in 29.3% of patients being treated with combination of vancomycin with piperacillintazobactam compared to 13.3% in patients treated with vancomycin in combination with
cefepime. 29 In a third study, incidence of AKI was 34.8% in the vancomycin and piperacillin-
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tazobactam combination group compared to 12.5% in the vancomycin and cefepime group. 30
There is also evidence of an increase in incidence of nephrotoxicity of vancomycin in
combination with piperacillin-tazobactam compared to vancomycin alone.6,15,25,26

There are a number of limitations associated with this study. This was a single center study
conducted at University of Kentucky Healthcare and, therefore, results may not be generalizable
to other hospitals serving different populations with differing levels of acuity. In addition, due to
the retrospective nature of this study, there are many variables with potential to affect results that
were unable to be collected, leading to residual confounding. One of these includes indication for
antibiotics or microbiology results. Piperacillin-tazobactam is a broad-spectrum antibiotic that is
often used for empiric therapy when an infection is suspected, however culture and
susceptibilities or source of infection are unknown. Once more information is known about an
infection, therapy is often switched to a more narrow-spectrum antibiotic such as nafcillin for an
MSSA infection. This is likely the reason the number of patients in each group is different with
the sample size in nafcillin being significantly smaller. This may also lead to nafcillin being used
for longer durations compared to piperacillin-tazobactam, which may only be used for a short
period of time before switching to an antibiotic targeting a specific bacterium.

Another limitation is temporality. This study assessed exposure to concomitant nephrotoxins,
hypotension, and dehydration at any point during a patient’s hospital stay rather than in relation
to development of AKI. The amount and duration of exposure was not analyzed, and exposure to
different nephrotoxins was treated the same and combined into a number of concomitant
nephrotoxins group, although different medications may have differing levels of nephrotoxicity.
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This study excluded patients in the piperacillin-tazobactam group who received vancomycin,
however included patients in the nafcillin group if they received up to 5 days of therapy with
vancomycin or piperacillin-tazobactam. This was due to the clinical use of nafcillin typically
being after initial treatment with a more broad-spectrum antibiotic such as piperacillintazobactam and/or vancomycin. The differing levels of exposure to vancomycin is another
limitation of this study and may have an effect on the odds of nephrotoxicity in nafcillin.
Exposure to vancomycin was excluded in the piperacillin-tazobactam group to try to isolate the
effect of the study drug. However, nephrotoxicity due to vancomycin is not expected to develop
within that timeframe; it has been shown that nephrotoxicity occurs after 7 days of therapy.27
Interestingly, time to AKI was longer in nafcillin, which is not what would be expected if
exposure to vancomycin was contributing to this effect.

Additionally, for patients transferred in from an outside hospital, information about their
previous hospital stay prior to coming to University of Kentucky Healthcare was not available to
be evaluated.

Another possible limitation is use of the RIFLE criteria as a measure of nephrotoxicity. Prior to
the introduction of the RIFLE criteria in 2004, a number of definitions of AKI were used. The
RIFLE criteria has been largely validated to identify AKI, classify severity, and correlate with
patient outcome.21-24 There has been an almost linear relationship seen between risk classification
in the RIFLE criteria and hospital mortality.23 The RIFLE criteria is limited by its requirement of
baseline renal function, or an estimate from the Modification of Diet in Renal Disease (MDRD)
equation. It has been modified in an attempt to increase sensitivity and specificity with the Acute
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Kidney Injury Network (AKIN) criteria, which was introduced in 2007. With the AKIN criteria,
baseline serum creatinine is not required. However, AKIN criteria could not be used in this study
because it requires adequate hydration status in order to diagnose AKI, which could not be
ensured due to the retrospective nature of this study.28 Although these limitations exist, it has
been shown that these two classification schemes are largely similar in identifying AKI and have
no difference in ability to predict mortality.29-31 Creatinine clearance is used to estimate GFR,
however it itself has limitations in its ability to measure kidney function. Biomarkers such as
neutrophil gelatinase-associated lipocalin (NGAL) are currently being investigated as new ways
to classify AKI earlier.32-34
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Conclusion

The odds of AKI overall and risk classification were higher in the nafcillin group compared to
the piperacillin-tazobactam group, although this difference did not persist in the injury and
failure categories. The mean time to AKI and hospital length of stay were longer in nafcillin
patients, and the incidence of mortality was also higher in the nafcillin group. This study
suggests that beta-lactam antibiotics overall may contribute to nephrotoxicity in adult
hospitalized patients, with nafcillin carrying a significantly greater potential for AKI than
piperacillin-tazobactam. However, further analysis should be done to assess the impact of risk
factors in contributing to this rate of nephrotoxicity since patients in the nafcillin group had
greater exposure to concomitant nephrotoxins and a longer duration of therapy. Future research
should further evaluate the findings of this study with a larger population assessing important
variables that could not be analyzed, such as site and type of infection and time and duration of
exposure to concomitant nephrotoxins, hypotension, and dehydration in relation to development
of AKI. It may also be beneficial to compare other beta-lactams or different dosing schemes.
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Tables and Figures
Figure 1: Sample Selection
31,854 total patients screened	


28,461 patients excluded:	

3,410 length of stay <2 days	

42 patient age <18 years	

15,211 patients did not receive nafcillin or piperacillin-tazobactam	

8,655 patients received piperacillin-tazobactam with vancomycin	

168 nafcillin patients with adjunct treatment >5 days	

40 patients with no serum creatinine values	

7 patients with baseline ClCr >4*SD+mean (~406 mL/min)	

148 patients with baseline ClCr <30 mL/min	

553 patients with antibiotic days of therapy <2 days	

64 patients had an AKI prior to treatment index	

150 patients had an AKI within 48 hours of treatment index	

13 patients had an AKI >5 days after treatment discontinued	


3,121 patients in piperacillin-tazobactam study group	


272 patients in nafcillin study group	
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Table 1: Demographic and Clinical Characteristics
Characteristic
Overall
Nafcillin group
n=3393
n=272
52.82 ± 17.48
54 (25)
1709 (50.37)

47.49 ± 15.61
47 (22)
175 (64.34)

Piperacillinp-value
tazobactam group
n=3121
53.28 ± 17.56
<0.0001c
54 (26)
1534 (49.15)
<0.0001e

Charlson
Comorbidity
Indexa,b
Baseline ClCr
(mL/min)a,b

3.42 ± 3.62
2 (4)

2.77 ± 3.19
2 (3)

3.47 ± 3.65
2 (4)

0.0084d

100.91 ± 42.89
95 (54.85)

106.9 ± 42.73
102.39 (54.69)

100.4 ± 42.87
94.36 (54.48)

0.0161c

Dehydration

233 (6.87)

15 (5.51)

218 (6.98)

0.3578e

Hypotension

393 (11.58)

51 (18.75)

342 (10.96)

0.0001e

609 (17.95)
142 (4.19)
28 (0.83)
165 (4.86)
14 (0.41)
13 (0.38)
1 (0.03)
679 (20.01)
365 (10.76)
25 (0.74)
69 (2.03)
22 (0.65)
1666 (49.10)

63 (23.16)
9 (3.31)
8 (2.94)
28 (10.29)
3 (1.10)
1 (0.37)
0 (0.00)
67 (24.63)
54 (19.85)
7 (2.57)
0 (0.00)
4 (1.47)
163 (59.93)

546 (17.49)
133 (4.26)
20 (0.64)
137 (4.39)
11 (0.35)
12 (0.38)
1 (0.03)
612 (19.61)
311 (9.96)
18 (0.58)
69 (2.21)
18 (0.58)
1503 (48.16)

0.0195e
0.4518e
0.0012f
<0.0001e
0.0959f
1.0000f
1.0000f
0.0470e
<0.0001e
0.0027f
0.0057f
0.0940f
0.0002e
<0.0001e

895 (26.38)
1476 (43.50)
784 (23.11)
203 (5.98)
35 (1.03)
4.93 ± 3.95
4 (3)

53 (19.49)
91 (33.46)
78 (28.68)
40 (14.71)
10 (3.68)
8.46 ± 9.96
5 (7)

842 (26.98)
1385 (44.38)
706 (22.62)
163 (5.22)
25 (0.80)
4.63 ± 2.67
4 (3)

Age (years)a,b
Male sex

Concomitant
nephrotoxins
ACEI
ARB
Acyclovir
Aminoglycosides
Amphotericin B
Cyclosporine
Foscarnet
Loop diuretics
NSAIDs
Sulfonamides
Tacrolimus
Tenofovir
IV contrast
Number of
concomitant
nephrotoxins
0
1
2
3
4+
Duration of
Therapy (days)a,b

<0.0001d

Data are number (percentage) unless otherwise indicated. ACEI = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ClCr =
creatinine clearance (adjusted Cockcroft-Gault); NSAID = non-steroidal anti-inflammatory drug; IV = intravenous.
a
Mean ± Standard Deviation, bMedian (Interquartile Range), cStudent’s T-test, dWilcoxon Rank Sum Test, eChi-Square Test, fFisher’s Exact Test
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Table 2: Antibiotic Exposure
Study Group
Antibiotic
Nafcillin group
Nafcillin only
Nafcillin + Piperacillin-tazobactam
Nafcillin + Vancomycin
Nafcillin + Piperacillin-tazobactam +
Vancomycin
Piperacillin-tazobactam
Piperacillin-tazobactam only
group
Data are number (percentage) unless otherwise indicated.

Frequency
41 (15.07)
2 (0.74)
90 (33.09)
139 (51.10)
3121 (100.00)
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Table 3: Cumulative Incidence of Acute Kidney Injury (Unadjusted)
Nafcillin with Concomitant Antibiotics ≤5 days vs. Piperacillin-tazobactam
Characteristic
Overall
Nafcillin group
Piperacillinn=3,393
n=272
tazobactam group
n=3,121
Acute Kidney
294 (8.66)
53 (19.49)
241 (7.72)
Injury, overall
Risk 230 (6.78)
38 (13.97)
192 (6.15)
Injury 47 (1.39)
10 (3.68)
37 (1.19)
Failure 17 (0.50)
5 (1.84)
12 (0.38)
Nafcillin only vs. Piperacillin-tazobactam
Characteristic
NAF
NP
NV
NPV
PTZ
n=41
n=2
n=90
n=139
n=3121
Acute Kidney 9 (21.95)
0 (0.00)
16 (17.78) 28 (20.14) 241 (7.72)
Injury, overall
Risk 7 (17.07)
0 (0.00)
11 (12.22) 20 (14.39) 192 (6.15)
Injury 1 (2.44)
0 (0.00)
4 (4.44)
5 (3.60)
37 (1.19)
Failure 1 (2.44)
0 (0.00)
1 (1.11)
3 (2.16)
12 (0.38)

p-value
<0.0001a

p-value
<0.0001b

Data are number (percentage) unless otherwise indicated. NAF = nafcillin only; NP = nafcillin + piperacillin-tazobactam; NV = nafcillin +
vancomycin; NPV = nafcillin + piperacillin-tazobactam + vancomycin.
a
Chi-Square Test
b
Fisher’s Exact Test
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Table 4: Adjusted Odds Ratio for Acute Kidney Injury for Nafcillin as compared to
Piperacillin-tazobactam
Nafcillin with Concomitant Antibiotics ≤5 days vs. Piperacillin-tazobactam
Primary Outcome
Odds Ratio (OR)
95% Confidence Interval
Acute Kidney Injury,
2.002
1.357
2.953
overall
Risk 1.799
1.162
2.786
Injury 2.246
0.958
5.264
Failure 2.357
0.685
8.113
Nafcillin only vs. Piperacillin-tazobactam
Primary Outcome
Odds Ratio (OR)
95% Confidence Interval
Acute Kidney Injury,
2.634
1.154
6.016
overall
Data analyzed using logistic regression. Adjusted for age, sex, Charlson Comorbidity Index, baseline creatinine clearance, hypotension, number
of concomitant nephrotoxins, and duration of therapy.
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Table 5: Time to Acute Kidney Injury, Hospital Length of Stay, and Mortality
Overall
Nafcillin group
Piperacillinn=294
n=53
tazobactam group
n=241
Time to Acute
Kidney Injurya,b

Hospital Length
of Staya,b
Mortality

p-value

4.93 ± 3.80
4 (4)

6.00 ± 5.14
5 (4)

4.69 ± 3.41
4 (4)

0.0458c

Overall
n=3,393

Nafcillin group
n=272

p-value

8.00 ± 8.30
5 (6)
135 (3.98)

14.38 ± 12.69
10 (11)
23 (8.46)

Piperacillintazobactam group
n=3,121
7.44 ± 7.55
5 (6)
112 (3.59)

Data are number (percentage) unless otherwise indicated.
a
Mean ± Standard Deviation, bMedian (Interquartile Range), cWilcoxon Rank Sum Test, dChi-Square Test

<0.0001c
<0.0001d
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